Erika Hamilton, MD

Bartsch R et al. Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial. ESMO Breast 2022;Abstract 165MO.

Devanaboyina M et al. A retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registry. ASCO 2021;Abstract 1031.

Hurvitz SA et al. Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial. Oncologist 2021;26(8):e1327-38. Abstract

Jerusalem GHM et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial. ASCO 2021;Abstract 526.

Stringer-Reasor EM et al. Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. ASCO 2021;Abstract 1044.

Vaz Batista M et al. Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study. SABCS 2021;Abstract PD4-06.

Sara A Hurvitz, MD

Cortés J et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022;386(12):1143-54. Abstract

Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.

Powell CA et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 2022;7(4):100554. Abstract

Tarantino P et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: A review. JAMA Oncol 2021;7(12):1873-81. Abstract

Ian E Krop, MD, PhD

Curigliano G et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol 2022;33(3):321-9. Abstract

Shanu Modi, MD

Bardia A et al. Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC): efficacy by Trop-2 expression in the TROPiCS-02 study of patients (pts) with HR+/HER2– metastatic breast cancer (mBC). SABCS 2022;Abstract GS1-11.

Diéras V et al. Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY). SABCS 2021;Abstract PD8-02.

Harbeck N et al. Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04. SABCS 2022;Abstract P1-11-01.

Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract

Prat A et al. Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04. SABCS 2022;Poster HER2-18.

Schettini P, Prat A. Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast 2021;59:339-50. Abstract

Schmid P et al. BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). ASCO 2021;Abstract 1023.

Sara M Tolaney, MD, MPH

Chan A et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer 2021;21(1):80-91.e7. Abstract

Loibl S et al. New therapies on the horizon for mTNBC. ESMO Virtual Plenary 2022;Abstract.

Piccart M et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up. J Clin Oncol 2021;39(13):1448-57. Abstract